LiquidiaLQDA
Recorded

Liquidia 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration47 minParticipants15

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, and welcome to the Liquidia Corporation Third Quarter 2026 Financial Results and Corporation Update Conference Call. My name is Lisa, and I will be your operator today. All participants are currently in listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions for joining the queue will be provided at that time. Please note that today's call is being recorded. I will now turn the call over to Jason Adair, Liquidia's Chief Business Officer.

Jason AdairChief Business Officer

Thank you, and good morning, everyone. It's my pleasure to welcome you to our Third Quarter 2026 Financial Results and Corporate Update Call. Joining me today are Dr. Roger Jeffs, Chief Executive Officer, Michael Kaseta, Chief Operating Officer and Chief Financial Officer, Dr. Rajeev Saggar, Chief Medical Officer, Scott Moomaw, Chief Commercial Officer, and Rusty Schundler, General Counsel. Before we begin, please note that today's discussion will include forward-looking statements, including statements regarding future results, our revenue outlook, product performance, and ongoing clinical or commercial activities. These statements are subject to risks and uncertainties that may cause actual results to differ materially. For further information, please refer to our filings with the SEC, which are available on our website. Please also note that our earnings release and our commentary include non-GAAP financial measures.

Jason AdairChief Business Officer

Reconciliations of these non-GAAP financial measures to the most comparable GAAP measure can be found in our earnings press release. With that, I'll turn the call over to Roger.

Roger JeffsCEO

Thank you, Jason, and good morning, everyone. Today's call comes at an important moment for Liquidia, and I want to be direct about what connects our extraordinary performance since launch to what lies ahead. Very simply, we see continued growth based on a differentiated product profile that provides unmatched advantages. As reported this morning, YUTREPIA has delivered five consecutive quarters of growth in prescriptions, revenue, and adjusted EBITDA. That trajectory is built on a product profile that delivers on our promise to improve how treprostinil reaches patients. With last month's settlement, the litigation overhang is behind us, YUTREPIA's future is secure, and we can focus entirely on the business. Let me be clear, the business is strong. Third quarter net product sales grew 31% to $222.7 million. PAH has been the core of that growth.

Roger JeffsCEO

From launch through the end of September, more than 60% of prescriptions included a PAH diagnosis, and in the month of September, it rose to over 70%. In October, the first full month after the recent ruling, total monthly shipments to patients reached their highest level since launch. Our settlement agreement does not require existing patients with PH-ILD to switch away from YUTREPIA, and we see no indication that providers, payers, or pharmacies have any desire to move PH-ILD patients benefiting from YUTREPIA to alternative therapies. Despite the disruption from the litigation and the temporary market ambiguity that it created, new referrals have held up well. In October, which we believe will be the month of greatest uncertainty, the daily referral rate was more than 75% of the daily rate in Q3.

Roger JeffsCEO

It should be noted that during the period between the court's ruling and our settlement, our competitor intentionally exacerbated prescriber uncertainty by sending a Dear Healthcare Provider letter suggesting that the ruling may require removal of YUTREPIA from the U.S. market entirely until the updated PH-only label is approved by the FDA. This speculative information created a slight pause in referrals at select centers, but we believe referrals will recover in the near term now that we have provided corrected communication directly to prescribers following the settlement, and October represents a floor and not a trend. With no change in formulary status or coverage, conversion rates remain greater than 87%, which we expect to continue. Of note, our prescriber base has continued to broaden and deepen since our last earnings call.

Roger JeffsCEO

With approximately 1,300 total prescribers, we were pleased to see more first-time prescribers in October than in September, while repeat prescribers continued to increase. Roughly 60% of our YUTREPIA prescribers have written for two or more patients, and more than 30% have written for at least five patients. Among our top 100 prescribers, average monthly referrals rose in October. Lastly, launched to date, 77% of prescribers have written for at least one PAH patient. Together, these prescribing trends give us confidence in YUTREPIA's continued growth and broad uptake. That confidence is grounded in the fact that YUTREPIA's product profile has not changed. Physicians choose YUTREPIA because it allows therapy to be individualized.

Roger JeffsCEO

They can titrate each patient's dose across a wide range, adjust the pace of titration based on each patient's experience, and unlike TYVASO and TYVASO DPI, YUTREPIA's label supports tailoring dose frequency to three, four, or five times daily based on the patient's needs, all of which can be delivered with a low-effort, palm-sized inhaler. YUTREPIA's flexibility is why we are growing our share in the PAH market, which continues to account for the majority of prostacyclin use. We estimate that approximately 80% of the roughly $4.9 billion in U.S. branded prostacyclin sales over the last four quarters was used to treat patients who have PAH. In fact, the PAH market is growing faster than many appreciate. That's partly because more patients are being identified, but more importantly, because the standard of care is shifting toward earlier, goal-oriented combination therapy, and the prostacyclin pathway is central to that shift.

Roger JeffsCEO

The World Symposium algorithm recommends an inhaled prostacyclin for patients who remain intermediate low risk and prostacyclin-containing triple therapy for patients who are higher risk. New mechanisms are being positioned as add-ons to background therapy, not replacements for it. We see this multimodal approach as additive to the prostacyclin market, as patients are living longer on therapy, all of which bodes well for YUTREPIA's continued growth as the field moves toward inhaled formulations that offer greater tolerability, dosing flexibility, and ease of use, which is the profile YUTREPIA was designed to deliver. To support continued growth, we also intend to keep building the evidence behind YUTREPIA's product profile. Our phase IV studies in PAH will continue, focused on dose flexibility, including three times daily dosing. We are actively screening patients into our study to define a transition algorithm from oral selexipag.

Roger JeffsCEO

In 2027, we plan to launch EASY-PAH, a registry study that will collect real-world data on the usage of YUTREPIA in PAH. Beyond PAH, we are studying YUTREPIA where patients have no approved option. For example, in systemic sclerosis associated with Raynaud's phenomenon, we are currently enrolling patients in RE-WARM, our dose-finding study, which we expect to complete in the first half of 2027. If successful, this would enable a pivotal study during the following winter seasons. We are also rapidly progressing studies of L606, our extended-release liposomal treprostinil, dosed twice daily with the next-generation nebulizer. RE-SPIRE, our global pivotal study in PH-ILD, continues as planned, with enrollment expected to complete in 2028. In parallel, our pivotal study in PAH, called AMPLIFY-PAH, will initiate in 2027 and help strengthen L606's competitive position in the market.

Roger JeffsCEO

Both studies are expected to advance on a similar timeline, with data expected to support a 505(b)(2) NDA submission in 2029. Lastly, we continue to actively prep for new studies in 2027 in indications where we believe our inhaled products will be the first or best choice for patients seeking treatment for pulmonary hypertension, like PH-COPD, for which we plan to initiate a pivotal study in the second half of next year. With that, I will turn the call over to Mike to share more detail on our financials and operating plan.

Michael KasetaCOO and CFO

Thank you, Roger. As stated earlier, the third quarter continued the growth trajectory we have delivered since launch. Net product sales of YUTREPIA were $222.7 million, up $52 million or 31% from last quarter. Of the total $222.7 million in total YUTREPIA sales, $212.2 million were paid patient demand sales, demonstrating strong product pull-through. On the expense side, cost of product sales grew in proportion to sales, and gross margin were similar to last quarter at approximately 94%. R&D expenses increased to $25.3 million, 47% higher than last quarter, as enrollment ramped in RE-SPIRE and new YUTREPIA studies started, but in line with guidance for the year. SG&A expenses were nearly flat compared to second quarter. As a percentage of revenue, SG&A fell from 33% in the second quarter to 26% in the third quarter, helping to highlight the operating leverage in our business.

Michael KasetaCOO and CFO

Cash and cash equivalents continued to build through the third quarter, ending with $396.1 million prior to the settlement payments, up $111.9 million from second quarter. This is nearly double the increase we saw between first and second quarter and further highlights the efficiency of our business. In total for the quarter, we reported a GAAP net loss of $236.3 million, which reflects a one-time settlement charge of $389.7 million, of which $380.7 million is payable in cash through April of 2027. Looking at non-GAAP measures, we saw adjusted EBITDA grow again to $140.5 million, our fifth consecutive quarterly increase. The strength of our balance sheet and our business will allow us to fully fund our objectives and payment obligations. We have no need to raise capital, and we are not changing our operating plan.

Michael KasetaCOO and CFO

With the final settlement payment in April and no royalty or ongoing payments due to United Therapeutics, the full benefit of YUTREPIA's growth in PAH will accrue to Liquidia and its shareholders. With that, I'll turn it back to Roger.

Roger JeffsCEO

Thanks, Mike. We recognize that for some investors, Liquidia is now a show-me story. We welcome that. We have what we believe is the best-in-class product in PAH, physicians who value its profile, and the resources to keep growing the sales line and the value of our pipeline. We look forward to sharing the fourth quarter results in early January. Operator, please open the line for questions.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day